Treatment of fibrotic interstitial lung disease: current approaches and future directions

Lancet. 2021 Oct 16;398(10309):1450-1460. doi: 10.1016/S0140-6736(21)01826-2. Epub 2021 Sep 6.

Abstract

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.

Publication types

  • Review

MeSH terms

  • Humans
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / therapy*
  • Pulmonary Fibrosis / drug therapy*
  • Pulmonary Fibrosis / therapy*